Traagiline
Traagiline is a prescription medication that belongs to the class of monoamine oxidase B (MAO-B) inhibitors. It is used in the management of Parkinson's disease to improve motor symptoms by increasing levels of dopamine in the brain through inhibition of the MAO-B enzyme, which normally degrades dopamine.
Indications for traagiline include its use as monotherapy in early Parkinson's disease or as an adjunct to
Mechanism of action involves selective and irreversible inhibition of MAO-B at typical clinical doses, leading to
Administration and pharmacokinetics: traagiline is usually given orally, with dosing tailored to the individual regimen. It
Adverse effects commonly observed include dyskinesia, nausea, dizziness, headache, insomnia, and orthostatic hypotension. Skin reactions and
Interactions and contraindications: avoid concomitant use with other MAO inhibitors or serotonergic drugs without medical supervision.